Oncology Central

Potential of circulating tumor cells as blood-based biomarkers in cancer liquid biopsy

0

Despite the first reports of circulating cells from solid tumors shed light on the circulation in deceased and in living patients in 1869 [1] and the mid 1950s [2], respectively, it took almost 50 years until the introduction of the CellSearch® system by Veridex (now Janssen Diagnostics, LLC, Raritan, NJ, USA) as well as its approval by the US FDA [3] in 2004 paved the way for widespread clinical assessment of the number of circulating tumor cells (CTCs) as a prognostic diagnostic tool.

To view restricted content, please:

Visit our Spotlight homepage now to discover more content hosted on Oncology Central as part of our Spotlight on circulating tumor cells.

Share:

Leave A Comment